Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TScan Therapeutics (TCRX) Total Debt (2022 - 2025)

Historic Total Debt for TScan Therapeutics (TCRX) over the last 4 years, with Q3 2025 value amounting to $32.4 million.

  • TScan Therapeutics' Total Debt rose 576.57% to $32.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $32.4 million, marking a year-over-year increase of 576.57%. This contributed to the annual value of $32.1 million for FY2024, which is 673.94% up from last year.
  • Per TScan Therapeutics' latest filing, its Total Debt stood at $32.4 million for Q3 2025, which was up 576.57% from $32.3 million recorded in Q2 2025.
  • TScan Therapeutics' 5-year Total Debt high stood at $32.4 million for Q3 2025, and its period low was $29.1 million during Q3 2022.
  • Moreover, its 4-year median value for Total Debt was $30.2 million (2024), whereas its average is $30.6 million.
  • Over the last 5 years, TScan Therapeutics' Total Debt had its largest YoY gain of 673.94% in 2024, and its largest YoY loss of 234.43% in 2024.
  • Over the past 4 years, TScan Therapeutics' Total Debt (Quarter) stood at $29.3 million in 2022, then increased by 2.58% to $30.0 million in 2023, then rose by 6.74% to $32.1 million in 2024, then rose by 1.07% to $32.4 million in 2025.
  • Its last three reported values are $32.4 million in Q3 2025, $32.3 million for Q2 2025, and $32.2 million during Q1 2025.